Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
Suchita Pakkala(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Sagar Lonial(Emory University), Gabriel Sica(Emory University), Walter J. Curran(Piedmont Cancer Institute), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), Tyler Beardslee(Emory University), Edmund K. Waller(Emory University), Kristin Higgins(Emory University), Conor Steuer(Emory University), Bassel Nazha(Emory University), Suresh S. Ramalingam(Emory University), Chao Zhang(Emory University), Mohammad Sohrab Hossain(Centre for the Rehabilitation of the Paralysed), Shuhua Wang(82th Hospital of Pla), Fadlo R. Khuri(American University of Beirut Medical Center), Guojing Zhang(Emory University)
Cited by 67
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k